Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma Rini BI; Rathmell WKClin Cancer Res 2007[Jan]; 13 (2 Pt 2): 741s-746sVascular endothelial growth factor (VEGF) is a key mediator in the pathogenesis of renal cell carcinoma (RCC). VEGF is up-regulated in clear cell RCC as a result of loss of the von Hippel-Lindau tumor suppressor gene and subsequent activation of the hypoxia response pathway. VEGF expression drives the migration and proliferation of endothelial cells to support the extensive angiogenesis in RCC. Strategies have been developed to bind and neutralize VEGF and have been investigated in RCC with promising results. Bevacizumab, a VEGF ligand-binding antibody, has shown prolonged time-to-progression versus placebo in treatment-refractory RCC patients and is being investigated currently in multiple RCC settings. VEGF-Trap is also a VEGF binding molecule with ongoing investigation in RCC.|*Gene Expression Regulation, Neoplastic[MESH]|Carcinoma, Renal Cell/*metabolism[MESH]|Cell Movement[MESH]|Cell Proliferation[MESH]|Clinical Trials as Topic[MESH]|Endothelium, Vascular/metabolism[MESH]|Humans[MESH]|Kidney Neoplasms/*metabolism[MESH]|Models, Biological[MESH]|Neoplasms/metabolism[MESH]|Neovascularization, Pathologic[MESH]|Protein Binding[MESH]|Up-Regulation[MESH]|Vascular Endothelial Growth Factor A/*metabolism[MESH] |
